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Aims To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with
permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients.
Methods
and results
Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm
(SR) and 243 (19%) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or pre-
scribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more
likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up.
During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per
100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57–
1.42), P ¼ 0.64 and 1.00 (0.60–1.66) P ¼ 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died
vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P, 0.001). Adjusted hazard
ratios of AVJ-abl vs. AF-Drugs was 0.26 [95% confidence interval (CI) 0.09–0.73, P ¼ 0.010] for all-cause mortality,
0.31 (95% CI 0.10–0.99, P ¼ 0.048) for cardiac mortality, and 0.15 (95% CI 0.03–0.70, P ¼ 0.016) for HF mortality.
Conclusion Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in
addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.
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Introduction
Cardiac resynchronization therapy (CRT) is an effective therapy
in symptomatic, optimally treated heart failure (HF) patients with
prolonged QRS duration and low ejection fraction (EF).1–4 Long-
term results of CRT on exercise tolerance and disease progression,
as evaluated by reversal of maladaptive remodelling process, are
rather limited5,6 and mostly reported in patients with sinus rhythm
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(SR). Permanent atrial fibrillation (AF) is a common arrhythmia in HF
patients and is associated with increased morbidity and mortality.7,8
Some studies have reported significant acute9,10 and short-term5,6
benefits of CRT in AF patients with HF. We recently11 emphasized
the importance of atrio-ventricular junction (AVJ) ablation in order
to optimize CRT in patients with permanent AF. This approach
appears to maximize CRT delivery, yielding a ‘pure’ resynchroniza-
tion effect which translates into significant long-term improvement
in left ventricular function and remodelling. Such a reverse remodel-
ling effect has been shown to correlate with improved survival in
HF patients with normal SR treated with CRT over mid-term
follow-up.12 To date, there is no information regarding this aspect
in HF patients with AF.
The aim of the present study was two-fold: first, to investigate
the effect of CRT on long-term survival in HF patients with perma-
nent AF compared with SR patients; second, to investigate whether
the adjunct of AVJ ablation may influence long-term outcome in
the AF patient subgroup.
Methods
Design
For the purpose of the present study, the data were derived from the
Multicentre Longitudinal Observational Study (MILOS)13 and included
all consecutive patients undergoing CRT pacemaker (CRT-P) or CRT
defibrillator (CRT-D) device implant from 1 August 1995 to 1 August
2004.
Patients
Among the 1303 patients enrolled in the registry, 18 had incomplete
data or were lost to follow-up: the remaining 1285 patients, who
represent the study population, were regularly followed in outpatient
clinic settings (at 2, 6, and every 6 months thereafter), where the physi-
cians were ‘blinded’ to the AVJ ablation therapeutic scheme; all
presented complete information about cardiac rhythm and survival
status; the last follow-up was scheduled on November 2004.
Aetiology was assessed in all cases by coronary angiography, and
causes of HF amenable to surgery or intervention were corrected at
least 6 months before device implantation. Because indication for
cardioverter–defibrillator therapy changed over time, patients
received the most appropriate device on the basis of current available
evidence and guidelines.
Two hundred and forty-three (19%) patients had permanent AF at
the time of implant, whereas the remaining 1042 were in SR. Immedi-
ately after CRT device implantation, every AF patient received negative
chronotropic drugs, and the rate adaptive mode plus specific pacing
features (such as ventricular rate regularization and/or trigger function)
were activated in order to maximize biventricular stimulation. AVJ
ablation was performed in patients in whom suboptimal CRT delivery
was observed. For all centres, the choice of performing AVJ ablation
was mainly based on the detection of inadequate BVP% derived
from device counters at 2 month post-implant control.11 In the
earlier phases, the evidence of frequent fusion, pseudo-fusion, or com-
petitive spontaneous beats detected from standard, dynamic, or stress
test ECG monitoring was utilized to further indicate AVJ ablation.
A BVP%  85 was considered ‘insufficient’ for effective CRT deli-
very. Therefore, in patients with BVP%  85, AVJ ablation was per-
formed; digoxin and amiodarone were subsequently suspended
(amiodarone was continued only if significant ventricular
tachyarrhythmias were present), whereas beta-blocker therapy was
maintained. On the contrary, patients with BVP% . 85 continued
throughout the follow-up the ‘rate-control’ treatment regimen com-
bining chronotropic negative drugs with activation of device features.
Because AVJ ablation was not a standardized clinical care, formal
approval was obtained from the review boards of each institution.
All patients gave their written informed consent to undergo the abla-
tion procedure under the understanding that irreversible complete
atrio-ventricular block would be created with subsequent pacemaker
dependency.
Adjudicated classification of deaths
Outcome data were collected at each participating centre by reviewing
outpatient clinical files or by phone interviews with relatives and/or
family doctors. At each centre, an adjudication committee was established
to perform chart review and assign, by consensus, the mode of cardiac
death. The adjudication committee was blinded to the strategy under-
taken to achieve rate control in AF patients as well as to the type of
implanted device. Deaths were classified as cardiac, non-cardiac, or
unknown. Cardiac deaths were classified as sudden (not preceded by
HF or ischaemic symptoms) or due to HF according to Epstein et al.14
Patients undergoing left ventricle assist device or urgent heart transplant
were classified as HF deaths. When the cause of death could not be
determined using all available sources, it was classified as unknown.
Device implantation and programming
Conventional ventricular leads were positioned in the right ventricular
apex in all patients implanted with CRT systems, and conventional
atrial leads were used only in SR patients. In those patients in whom
implantable defibrillator was necessary, the defibrillation lead was posi-
tioned in the right ventricular apex. Transvenous left ventricular lead
positioning was guided by coronary sinus venogram, preferring a
lateral or postero-lateral vein as implantation site. In case of failure
or technical difficulties by the transvenous approach (phrenic nerve
stimulation, inability to cannulate the coronary sinus, etc.), epicardial
screw-in or steroid-eluting passive lead was implanted through
limited thoracotomy. The latter was the elective approach used
before transvenous leads became routinely available.
In patients with preserved SR, devices were programmed in DDD
modality, usually with a minimum heart rate of 50 b.p.m., and atrio-
ventricular interval optimization was performed.15 In patients with
AF, minimum heart rate was usually set at 70 b.p.m. (80 b.p.m. for
2 weeks after AVJ ablation).16 Rate adaptive response was activated
in any AF patient and the maximum rate was set at 85% of the
theoretical maximum heart rate; moreover, in order to achieve the
higher biventricular pacing percentage, ventricular rate stabilization
and/or ventricular rate regulation (VRR) and trigger mode were acti-
vated when available.17
Statistical analysis
Descriptive statistics were computed as mean and standard deviation
for continuous variables and as counts and percentage for categorical
variables. Patients’ characteristics were compared between groups
with unpaired t-test or one-way analysis of variance and with Fisher’s
exact test, respectively. Median follow-up and its 25–75th percentiles
were computed by means of the inverse Kaplan–Meier method.18 The
rates of fatal and of cardiac events per 100 person-year and their 95%
confidence intervals (95% CIs) were calculated. Kaplan–Meier method
was used to compute cumulative event-free survival. Cox regression
was used to assess the prognostic role of the presence of AF when
compared with SR and, among AF patients, the presence or absence
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of AVJ ablation, while adjusting for a series of potential baseline con-
founders (age, gender, left ventricular EF, aetiology, QRS duration,
functional NYHA class, and the type of implanted device—CRT-P or
CRT-D), in a multivariable model stratified for centre. Hazard ratios
(HRs) and their 95% CI were reported. The proportional hazard
assumption was verified, based on Schoenfeld residuals. AVJ ablation
was treated as a time-dependent variable. To better characterize the
prognostic role of AF and AVJ ablation on the different causes and
modes of death, separate Cox models were fitted for cardiac death,
death from HF, and sudden death. In these cases, to avoid overfitting,
confounding was addressed by including the quintiles of the propensity
score (PS) in the Cox model stratified by centre. The PS is a measure
of the likelihood for a patient to undergo AVJ, given its presenting
characteristics, derived from a multivariable logistic model. To build
the PS, we included in the model all the demographic and clinical vari-
ables collected (age, gender, left ventricular EF, aetiology, QRS dura-
tion, functional NYHA class, the type of implanted device, and
centre), together with their two-way interactions, as well as the drug
regimen administered (Table 1). The balancing property of the PS
was satisfied and the c-statistic for the model was computed to 0.80.
Moreover, the ability of the PS to control for confounding in the
subsequent Cox models was confirmed by its lack of statistical
significance.
Stata 9 (StataCorp, College Station, TX, USA) was used for compu-
tation. A two-sided P-value ,0.05 was considered statistically significant.
Results
Long-term survival stratified according
to baseline rhythm
The characteristics of the 1042 patients in SR are compared with
those of the 243 patients with permanent AF in Table 1. The
two groups had similar severity of symptoms as shown by their
NYHA class and need of intravenous inotropic therapy. Patients
with AF were older, with a greater prevalence of female gender,
less coronary artery disease, slightly higher EF, and marginally
shorter QRS duration. AF patients received less CRT-D devices
and were more often treated with digoxin, amiodarone, and nega-
tive chronotropic drugs (to achieve a higher percentage of biven-
tricular pacing time).
During a median follow-up of 34 months (interquartile range:
10–40 months), 170/1042 and 39/243 patients in the SR and AF
groups died, with a mortality rate of 8.4 (95% CI 7.2–9.8) and
8.9 (95% CI 6.5–12.2) per 100 person-year (Figure 1A), respect-
ively. Multivariable analysis confirmed similar mortality of SR and
AF patients (HR 0.90, 95% CI 0.57–1.42, P ¼ 0.64).
The cause of death could not be established in only six cases
(four patients in SR and two in AF) and were therefore classified
as unknown. One hundred and sixty-nine patients died from
cardiac death, 135/1042 and 34/243 in the SR and AF groups,
respectively. Cardiac death rates were 6.7 (95% CI 5.6–7.9) and
7.7 (95% CI 5.5–10.8) per 100 person-year in SR and AF patients,
respectively (Figure 1B). No difference in cardiac mortality was
found between patients in SR and AF both at univariable and multi-
variable analyses (adjusted HR 1.00, 95% CI 0.60–1.66, P ¼ 0.991).
Worsening HF was the most important mode of death in
both groups accounting for 105/1042 deaths in SR patients and
for 28/243 deaths in patients with AF, a mortality rate of 5.2
(95% CI 4.3–6.3) and 6.3 (95% CI 4.4–9.2) per 100 person-year,
respectively (Figure 1C). No difference in adjusted HR for HF
death (1.18, 95% CI 0.67–2.06, P ¼ 0.564) was found.
Long-term survival of atrial fibrillation
patients stratified according to
atrio-ventricular junction ablation
The AF population was subdivided depending on whether the
modality used to control heart rate was by negative chronotropic
drugs (AF-Drugs) or AVJ ablation (AVJ-abl). The two groups
were similar with respect to some of their main baseline chara-
cteristics (Table 2), including age, gender, aetiology, NYHA class,
and pharmacological therapy. Patients in the AVJ-abl group
had a shorter QRS duration and less frequently received
CRT-D. Moreover, the use of negative chronotropic drugs, in
the first 2–3 months after CRT implant, was similar between the
two groups and dosages were adequate. Of the 243 patients,
240 were still alive at the 2 month follow-up: three AF patients
died before this scheduled visit (two on drug therapy and one
extremely compromised patient, who underwent AVJ ablation
soon after CRT implantation and died from refractory HF before
discharge).
At the 2-month control, 123 patients reached BVP% . 85
(mean 89.4+ 2.4%) and continued negative chronotropic drugs
throughout the follow-up to maintain adequate BVP% (AF-Drugs
group). The other 117 AF patients with BVP%  85 at 2 months
(mean 74.2+4.2%) underwent AVJ ablation within 3 months
from device implant (AVJ-abl group). AVJ ablation was effective
in 98.4% of cases, no major complications occurred. Once ablation
of the AVJ was performed, digoxin and amiodarone were discon-
tinued (amiodarone was continued only in cases presenting rel-
evant ventricular tachyarrhythmias), whereas beta-blockers were
maintained. At the following control after AVJ ablation, device
counters revealed full biventricular pacing effectiveness, with
BVP% nearing 100 (mean 98.7+ 1.8%). The evaluation of drug
therapy modifications in the AF group was performed after
1 year of CRT. Dosage of beta-blockers increased compared
with baseline (carvedilol increased from 14.6 to 19.5 mg/day,
P, 0.001). No differences were detected in either beta-blocker
or ACE-inhibitor usage between the two AF patient groups.
A total of 39 deaths occurred in AF patients. Of these events,
28/125 patients were observed in the AF-Drugs group and 11/118
patients in AVJ-abl group (Figure 2A), with mortality rates of 14.2
(95% CI 9.7–20.5) and 4.6 (95% CI 2.5–8.2) per 100 person-year,
respectively (Figure 2A). Total mortality was therefore significantly
better in the AVJ-abl group compared with the AF-Drugs group
(adjusted HR 0.26, 95% CI 0.09–0.73, P ¼ 0.010, Figure 3).
With respect to the cause of death, cardiac deaths occurred in
24/125 patients of the AF-Drugs group compared with 10/118
patients in the AVJ-abl group (Figure 2B), with cardiac mortality
rates of 12.1 (95% CI 8.1–18.1) and 4.1 (95% CI 2.2–7.7) per
100 person-year, respectively (Figure 2B), and an adjusted HR of
0.31 (95% CI 0.10–0.99, P ¼ 0.048) for AVJ-abl vs. AF-Drugs
patients (Figure 3).
A total of 28 events (death or urgent heart transplant or left
ventricular assist device positioning) occurred as a result of
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worsening HF with an incidence of 22/125 in the AF-Drugs group,
as opposed to only 6/118 in the AVJ-abl group, with a mortality
rate of 11.1 per 100 person-year (95% CI 7.3–16.9) in the
AF-Drugs group and of only 2.5 (95% CI 1.1–5.5) per 100 person-
year in the AVJ-abl group (Figure 2C) (adjusted HR 0.15, 95% CI
0.03–0.70, P ¼ 0.016) (Figure 3).
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Table 1 Baseline characteristics of global permanent atrial fibrillation patient
population compared with sinus rhythm patients
SR (n5 1042) AF (n5 243) P-value
Age (years) 63.4 (9.5) 66.2 (8.9) ,0.001
Female 262 (25.1%) 44 (18.1%) 0.020
Aetiology
Non-ischaemic 545 (52.3%) 146 (60.0%) 0.032
Ischaemic 497 (47.7%) 97 (40.0%)
NYHA
II 60 (5.8%) 10 (4.1%) 0.196
III 826 (79.3%) 193 (79.4%)
IV 146 (14.9%) 40 (16.5%)
QRS (ms) 170 (28) 161 (32) ,0.001
Left ventricular EF (%) 24.4 (7.3) 26.0 (8.0) 0.005
Mitral regurgitation (grade 3–4) 594 (57%) 185 (76%) ,0.001
Left atrial diameter (mm) 51 (7) 56 (6) ,0.001
CRT-D 604 (57.8%) 117 (48.2%) 0.006
ACE-inhibitors/ARBs 948 (90.9%) 228 (93.7%) 0.162
Beta-blockers 833 (79.9%) 194 (79.7%) 1.000
Aldosterone antagonists 548 (52.6%) 140 (57.6%) 0.175
Diuretics 938 (90.0%) 224 (92.2%) 0.335
Digitalis 550 (52.9%) 171 (70.3%) ,0.001
Amiodarone 259 (24.9%) 108 (44.4%) ,0.001
Negative chronotropic drugs 907 (87.0%) 236 (97.1%) ,0.001
Intravenous inotropic drugs 12 (1.2%) 5 (2.0%) 0.344
Mean (SD) for continuous variables; n (%) for categorical variables.
SR, sinus rhythm; AF, atrial fibrillation; CRT-D, cardiac resynchronization therapy pacemaker with defibrillator; ARBs,
angiotensin receptor blockers.
Figure 1 Comparison of Kaplan–Meier estimates of overall (A), cardiac (B), and heart failure (C) survival between sinus rhythm and the global
atrial fibrillation population. The P-values presented derive from the adjusted hazards ratio analysis stratified according to the corresponding
cause of death.
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Table 2 Baseline characteristics at the time of cardiac resynchronization therapy
implant of the permanent atrial fibrillation patient population divided according to
atrio-ventricular junction ablation (AVJ-abl) or drugs (AF-Drugs) for rate control
AF-Drugs (n5 125) AVJ-abl (n5 118) P-valuea
Age (years) 65.9 (8.6) 66.5 (9.2) 0.893
Female 28 (22.4%) 16 (13.6%) 0.074
Aetiology
Non-ischaemic 77 (61.6%) 69 (58.5%) 0.694
Ischaemic 48 (38.4%) 49 (41.5%)
NYHA
II 4 (3.2%) 6 (5.1%) 0.733
III 101 (80.8%) 92 (78.0%)
IV 20 (16.0%) 20 (17.0%)
QRS (ms) 168 (29) 155 (34) 0.010
Left ventricular EF (%) 24.8 (7.6) 27.0 (12.0) 0.087
Mitral regurgitation (grade 3–4) 97 (78%) 88 (75%) 0.652
Left atrial diameter (mm) 57 (8) 55 (9) 0.068
Mean resting heart rate (b.p.m.) 73 (7.2) 77 (9.1) ,0.001
CRT-D 69 (55.2%) 48 (40.7%) 0.029
ACE-inhibitors/ARBs 117 (93.5%) 111 (94.1%) 1.000
Beta-blockers 102 (81.6%) 92 (78.0%) 0.524
Aldosterone antagonists 67 (49.6%) 73 (61.9%) 0.198
Diuretics 118 (96.6%) 106 (89.8%) 0.234
Digitalis 92 (73.6%) 79 (66.9%) 0.265
Amiodarone 60 (48.0%) 48 (40.7%) 0.302
Negative chronotropic drugs 123 (98.4%) 113 (96.6%) 0.270
Intravenous inotropic drugs 2 (1.6%) 3 (2.7%) 0.676
Mean (SD) for continuous variables; n (%) for categorical variables.
AVJ-abl, atrial fibrillation patients who underwent atrio-ventricular junction ablation; AF-Drugs, atrial fibrillation patients
who did not undergo atrio-ventricular junction ablation; CRT-D, cardiac resynchronization therapy pacemaker with
defibrillator; ARBs, angiotensin receptor blockers.
aFor post hoc comparisons, Scheffe´’s test was used after one-way anova; after Fisher’s exact test, the level of significance was
set to 0.017 for Bonferroni correction.
Figure 2 Comparison of Kaplan–Meier estimates of overall (A), cardiac (B), and heart failure (C) survival between atrial fibrillation patients
who underwent atrio-ventricular junction ablation (AVJ-abl) and atrial fibrillation patients treated only with negative chronotropic drugs
(AF-Drugs). The P-values presented derive from the adjusted hazards ratio analysis stratified according to the corresponding cause of death.
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The occurrence of sudden cardiac death was very rare and
accounted for only two events in the AF-Drugs (1.01, 95% CI
0.3–4.1 per 100 person-year) and four events in the AVJ-abl
group (1.7, 95% CI 0.6–4.4 per 100 person-year). Adjusted HR
was 2.59 (95% CI 0.22–30.15, P ¼ 0.370).
Discussion
CRT confers significant reductions in left ventricular volumes and
improvement of left ventricular EF in HF patients.3,11 Such favour-
able changes have shown to correlate with mortality reduction
over a mid-term follow-up in SR patients.12 We recently11
described significant long-term improvements in left ventricular
EF and left ventricular reversal of maladaptive remodelling in AF
patients treated with the combined CRT and AVJ approach. In
AF patients with preserved AVJ conduction, however, no such
improvements were observed. No consistent correlation has
been reported until now between reverse remodelling and mor-
tality reduction after CRT in AF patients. The present study may
be considered an extension of the previous one11 and aimed to
evaluate, in a much larger patient cohort, whether the effect
of the combined AVJ ablation and CRT strategy may also
translate into favourable long-term survival of HF patients with
permanent AF.
To our knowledge, this is the first study comparing outcomes
among patients treated with CRT, between those in SR and
those with AF, and, even more importantly, among patients with
AF, based on whether or not these patients underwent AVJ abla-
tion. The dramatic difference in mortality rate observed between
AF-drugs and AF-abl could support the view that AVJ ablation
may be strongly recommended to achieve effective CRT in AF
patients. However, our data should be confirmed by prospective
randomized trials, possibly comparing in these patients VVIR-ICD
and rate control vs. CRT-DþAVJ ablation.19
Effects of cardiac resynchronization
therapy in heart failure patients with
permanent atrial fibrillation compared
with sinus rhythm
Despite a 20% prevalence of AF among HF patients treated with
CRT,13 randomized controlled CRT trials have generally included
only patients in SR. Therefore, there are virtually no data
investigating the effects of CRT on survival in HF patients with
permanent AF.
Both ventricular conduction delay and AF are associated with a
poor prognosis in HF patients.7,8 CRT may be therefore indicated
in these patients. Small studies have shown beneficial effects of
CRT also in patients with HF and AF, with an improvement in
NYHA class, exercise capacity, and quality of life.6,20,21
In the present study, the multivariable analysis did not detect any
significant differences in overall, cardiac, and HF long-term mor-
tality rates between patients in SR and in permanent AF. Our
recent contribution11 described similar long-term improvements
in left ventricular EF and left ventricular reversal of maladaptive
remodelling between SR and AF patients treated with CRT. In
this study, mean left ventricular EF increase at 1 year was of
6.5% absolute units in both the SR group and the AF group, with
a concomitant decrease in the left ventricular end-systolic
volume of 20% in the SR patients compared with 15% in the
Figure 3 Hazard ratio estimates stratified according to cause of death between atrial fibrillation patients who underwent atrio-ventricular
junction ablation (AVJ-abl) and atrial fibrillation patients treated with negative chronotropic drugs (AF-Drugs); hazard ratio estimates were
adjusted for centre, age, gender, aetiology, NYHA class, QRS width, left ventricular ejection fraction, and device type. Corresponding
hazard ratio values for each cause of death are indicated with a square, the bar represents 95% confidence interval range, and the P-value
for each estimate is presented on the right of the figure.
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AF group. These results are consistent with the similar mortality
rates that we observed in our patients with either SR or AF.
Importance of atrio-ventricular junction
ablation in patients with permanent
atrial fibrillation
It is important to point out that studies5,11,20,21 reporting benefits
of CRT in permanent AF included patients with either a low ven-
tricular rate or a previously ablated AVJ. This situation is, however,
not frequent in clinical practice and many patients with AF have a
high ventricular rate (at least during exertion) despite concomitant
treatment with negative chronotropic AF-Drugs (e.g. beta-
blockers, digitalis, amiodarone). Moreover, the activation of rate-
smoothing features such as VRR or trigger mode may effectively
regularize heart rate, whereas forcing faster heart rates may
become deleterious.
Hence, AVJ ablation may be the only procedure allowing a ‘com-
plete’ heart rate control in these patients. Such a procedure offers
the advantage of obtaining a regular ventricular rhythm and, prob-
ably more importantly, ensures effective CRT through pure and
constant biventricular pacing. Achievement of a regular ventricular
rhythm through AVJ ablation has been associated with an improve-
ment in global cardiac mechanics.22 AVJ ablation may therefore find
an elective indication in HF patients treated with CRT, as it should
allow greater benefits compared with those observed in the
general population in which the ‘ablate and pace’ strategy is con-
ventionally used to obtain a more regular and slower heart
rhythm.23,24 Another possible explanation for the impressive
effects on survival obtained as a result of AVJ ablation may be
related to the fact that, after AVJ ablation, most patients suspended
both digoxin and amiodarone: data derived from randomized trials
suggest that digoxin25 and amiodarone26 may have a negative
impact on morbidity and mortality in HF patients.
Recently published data11 have suggested that in HF patients
with AF, CRT confers long-term improvements of EF, end-systolic
volume, NYHA class, and exercise capacity only in patients who
undergo AVJ ablation. Such extensive improvements in EF and in
left ventricular geometry have already been correlated to favour-
able prognosis in HF patients in SR.12 The previous findings advo-
cating that AVJ ablation optimizes CRT delivery thus yielding a
significant reverse remodelling effect11 are consistent with what
has been described in the present study. The analysis of the differ-
ent death modes, stratified on the propensity of a patient being
ablated, given its presenting characteristics, allowed to elucidate
the role of AVJ ablation in patients with permanent AF treated
with CRT. Overall, cardiac and HF deaths were significantly
lower in AF patients who underwent AVJ ablation compared
with those who were not ablated. This survival benefit was
mainly due to the protective effect of AVJ ablation on deaths for
HF. AF patients who underwent AVJ ablation had a nine-fold
lower HF mortality compared with non-ablated AF patients.
Kaplan-Meier analysis revealed that the time pattern of survival
for HF becomes apparent after 4 months of CRT; this time
point, shortly after AVJ ablation, corresponds to the same period
when the reverse remodelling process becomes manifest in the
AVJ-abl population.11 Taken together, these findings suggest, as
previously described in SR patients,12 that the reverse remodelling
effect produced by CRT may translate to a lower incidence of HF
death in the AVJ-abl group.
No clear statement may be made regarding possible effects on
mortality from sudden cardiac death in AF patients treated with
CRT, due to the low number of sudden death events that occurred
in our patient cohort and due to the significant difference in
patients receiving ICD back-up between the two groups.
Study limitations
This observational study has several limitations, being a non-
randomized study; to consider, however, our cohort of 1285
patients with a median follow-up of 34 months represents one
of the largest series evaluating the effects of CRT reported so
far. It may have been useful to have an AF control group not
treated with CRT, but the data are derived from a pre-defined
CRT registry of consecutively implanted patients. Also, outcome
may have been biased by patients’ selection and changes in both
pharmacological and non-pharmacological therapies over the
study period. One limitation may be the lack of a ‘direct’ corre-
lation between remodelling effect and mortality data. Unfortu-
nately, only two of the four centres rigorously collected
follow-up echocardiographic data. For this reason, the obser-
vations of the present study were interpreted and integrated
with the findings of the previous contribution.11
The limits posed by the differences in the baseline characteristics
between the study groups were mitigated by the statistical analysis
which considered possible confounding effects of centre, gender,
age, aetiology, QRS duration, functional NYHA class, baseline left
ventricular EF, and device type in the fitted models. Moreover,
to avoid over-fitting, confounding was addressed by adjusting the
Cox models by the quintiles of the PS. Given the longitudinal,
observational design of the study, even these adjusted models
may not guarantee complete suppression of some confounders,
hence the need for confirmatory randomized studies.
Although the AF group was numerically inferior to the SR group,
the subdivision of AF patients in AVJ-abl and AF-Drugs resulted in
two numerically balanced groups with similar baseline character-
istics. Finally, the declining number of patients over the follow-up
may represent a limitation, but this is the case of any observational
cohort study. All the available patients were included and only few
patients were either lost to follow-up or had incomplete outcome
data; the latter were excluded from the study.
Conclusions
In our large multicentre series, the long-term overall survival of
drug refractory HF patients with permanent AF and left ventricular
conduction delay treated with CRT was similar to that of SR
patients. However, in HF patients with permanent AF, AVJ ablation
in addition to CRT appears to improve long-term overall mortality
compared with CRT alone, primarily by reducing HF death. AVJ
ablation seems to be a fundamental adjunct to ensure adequate
CRT delivery and thus reducing mortality in patients with per-
manent AF. Prospective randomized studies are necessary to
further confirm these findings.
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Hunting rifle shot to the chest: a rare cause of myocardial infarction
Alban-Elouen Baruteau, Raphae¨l Pedro Martins, and Dominique Boulmier*
Department of Cardiology, CHU Pontchaillou, University Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France
* Corresponding author. Tel: þ33 299 282 525, Fax: þ33 299 282 510, Email: dominique.boulmier@chu-rennes.fr
A 46-year-old man without cardiovascular
risk factors was shot in the chest with
a hunting rifle 1 month before this evaluation
(Panel A). He underwent emergency surgery
for haemorrhagic shock because of right and
left ventricular tears. Upon his discharge
from the intensive care unit, electrocardio-
graphic changes consistent with apico-lateral
infarction were noted, and trans-thoracic
echocardiography revealed the presence of
apical akinesia, with a left ventricular ejection
fraction at 45%. Coronary angiograms (Panel
B) showed a short 50% stenosis of the distal
left anterior descending (LAD) coronary
artery, followed by post-stenotic aneurysmal
dilatation (arrow) and normal coronary flow.
On 64-slice computed tomography (Panels
C and D), 253 rifle pellets were observed
in the mediastinal region; of which five
were lodged in the interventricular septum
and one was in contact with the distal
LAD, adjacent to the stenosis (circle). We
hypothesized two possible mechanisms: (i)
a blast effect with dissection, thrombosis,
or both, secondary to intimal tear; (ii) vascu-
lar stenosis secondary to oedema or parietal
haematoma by myocardial contusion. The patient was placed on a regimen of anti-platelet agents, beta-adrenergic blocker, angiotensin-
converting enzyme inhibitor, and statin, and has remained free of cardiovascular complication at 1 year of follow-up.
Panel A. Postero-anterior chest roentgenogram. Innumerable rifle pellets are visible, mostly in the precordial area and left lower
lung field.
Panel B. Selective angiography of the left coronary artery in the right anterior oblique projection. Innumerable rifle pellets overlie
the precordial region. See text for details.
Panel C. 64-slice computed tomography (long axis view). See text for details.
Panel D. 64-slice computed tomography (maximum intensity projection and volume rendering). See text for details.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
M. Gasparini et al.1652
